Last reviewed · How we verify
Taclonex Topical Suspension
Taclonex combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis.
Taclonex combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis.
At a glance
| Generic name | Taclonex Topical Suspension |
|---|---|
| Sponsor | University of Pittsburgh |
| Drug class | Combination topical agent (vitamin D analog + corticosteroid) |
| Target | Vitamin D receptor (VDR) and glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Calcipotriene acts as a vitamin D receptor agonist that promotes differentiation and reduces proliferation of keratinocytes, while betamethasone dipropionate provides potent anti-inflammatory effects through glucocorticoid receptor activation. Together, these agents work synergistically to reduce the erythema, scaling, and plaque formation characteristic of psoriasis.
Approved indications
- Plaque psoriasis
Common side effects
- Skin irritation or burning
- Pruritus
- Skin atrophy (with prolonged use)
- Folliculitis
Key clinical trials
- Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
- Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
- Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris (PHASE2)
- To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis (PHASE1)
- To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis (PHASE3)
- Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris (PHASE4)
- BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis (PHASE1)
- An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taclonex Topical Suspension CI brief — competitive landscape report
- Taclonex Topical Suspension updates RSS · CI watch RSS
- University of Pittsburgh portfolio CI